A collaborative study with Texas Tech University Health Sciences Center that builds upon a prior KCP discovery of an inflammed subtype of renal cancer shows increased deposition of complement proteins in inflamed renal tumors. The data suggest that complement proteins, which are associated with poor prognosis, may suppress an adaptive immune response and could be targeted in combination with immune checkpoint inhibitors.
